SAR439459 + Placebo
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteogenesis Imperfecta
Conditions
Osteogenesis Imperfecta
Trial Timeline
Aug 25, 2022 → Nov 12, 2024
NCT ID
NCT05231668About SAR439459 + Placebo
SAR439459 + Placebo is a phase 1 stage product being developed by Sanofi for Osteogenesis Imperfecta. The current trial status is terminated. This product is registered under clinical trial identifier NCT05231668. Target conditions include Osteogenesis Imperfecta.
What happened to similar drugs?
1 of 7 similar drugs in Osteogenesis Imperfecta were approved
Approved (1) Terminated (2) Active (4)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05231668 | Phase 1 | Terminated |
Competing Products
16 competing products in Osteogenesis Imperfecta
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide (FORTEO) + Placebos | Eli Lilly | Approved | 43 |
| Zoledronic Acid | Novartis | Phase 2 | 35 |
| Zoledronic Acid | Novartis | Phase 2 | 35 |
| Zoledronic Acid | Novartis | Phase 3 | 40 |
| Romosozumab + Bisphosphonate | Amgen | Phase 3 | 47 |
| Romosozumab | Amgen | Phase 1 | 29 |
| Denosumab | Amgen | Phase 3 | 32 |
| Denosumab + Alternative osteoporosis medications | Amgen | Phase 3 | 32 |
| Fresolimumab | Sanofi | Phase 1 | 29 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 29 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2/3 | 36 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2 | 21 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 21 |
| setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 38 |
| setrusumab + zoledronic acid (optional) | Ultragenyx Pharmaceutical | Phase 2 | 29 |
| Bisphosphonate + Setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 38 |